Literature DB >> 28707152

[177Lu-PSMA radioligand therapy for advanced prostate cancer].

T Derlin1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28707152     DOI： 10.1007/s00117-017-0283-2

Source DB:  PubMed          Journal:  Radiologe        ISSN： 0033-832X            Impact factor:   0.635


× No keyword cloud information.
  3 in total

1.  Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.

Authors:  Sebastian Schmuck; Stefan Nordlohne; Christoph-A von Klot; Christoph Henkenberens; Jan M Sohns; Hans Christiansen; Hans-Jürgen Wester; Tobias L Ross; Frank M Bengel; Thorsten Derlin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-09       Impact factor: 9.236

2.  High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.

Authors:  Sarah Minner; Corinna Wittmer; Markus Graefen; Georg Salomon; Thomas Steuber; Alexander Haese; Hartwig Huland; Carsten Bokemeyer; Emre Yekebas; Judith Dierlamm; Stefan Balabanov; Ergin Kilic; Waldemar Wilczak; Ronald Simon; Guido Sauter; Thorsten Schlomm
Journal:  Prostate       Date:  2010-08-31       Impact factor: 4.104

Review 3.  Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.

Authors:  N Nussbaum; D J George; A P Abernethy; C M Dolan; N Oestreicher; S Flanders; T B Dorff
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-02-02       Impact factor: 5.554
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.